BridgeBio developing therapies with Columbia University, Mount Sinai

By The Science Advisory Board staff writers

October 29, 2021 -- BridgeBio Pharma announced it is collaborating with Columbia University and Mount Sinai Health System to develop potential therapies to treat individuals with genetic diseases and cancers.

The company has initiated 25 collaborations with leading institutions around the world that are focused on providing therapeutic options to patients with unmet needs.

BridgeBio noted Columbia University and Mount Sinai's respective expertise in developing breakthroughs for patients with genetic diseases and genetically driven cancers.

Copyright © 2021

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter